Neurocrine Biosciences

Showing 4 posts of 4 posts found.


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

September 12, 2023
Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …

FDA approves first endometriosis pain management drug in a decade

July 25, 2018
Research and Development, Sales and Marketing AbbVie, FDA, Neurocrine Biosciences, endometriosis, pharma

The FDA has confirmed its approval of AbbVie and Neurocrine Biosciences’ Orilissa (elagolix), a nonpeptide small molecule gonadotropin-releasing hormone (GnRH) …


Neurocrine’s Ingrezza flops in Tourette’s for second time

May 25, 2017
Research and Development, Sales and Marketing Neurocrine Biosciences, tourette's

Neurocrine’s Tourette’s therapy Ingrezza (valbenazine) has been hit with yet another setback, flopping in a Phase 2 trial of paediatric …


FDA approves first and only tardive dyskinesia treatment

April 12, 2017
Research and Development, Sales and Marketing FDA, Neurocrine Biosciences, tardive dyskinesia

US patients suffering with tardive dyskinesia (TD) will see access to the first approved treatment in the country with the …

Latest content